AbbVie (ABBV) Stock Forecast & Price Target

$264.45 -0.67 (-0.25%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$264.60 +0.15 (+0.06%)

As of 09/25/2026 07:59 PM Eastern

Compare

AbbVie - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 25 Analyst Ratings

Sell
0

Hold
5

Buy
20

Based on 25 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 25 analysts, 5 have given a hold rating, 18 have given a buy rating, and 2 have given a strong buy rating for ABBV.

Consensus Price Target

$276.64
4.61% Upside

According to the 25 analysts' twelve-month price targets for AbbVie, the average price target is $276.64. The highest price target for ABBV is $315.00, while the lowest price target for ABBV is $223.00. The average price target represents a forecasted upside of 4.61% from the current price of $264.45.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ABBV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABBV Analyst Ratings Over Time

Type	Current Forecast 9/26/25 to 9/26/26	1 Month Ago 8/27/25 to 8/27/26	3 Months Ago 6/28/25 to 6/28/26	1 Year Ago 9/26/24 to 9/26/25
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	3 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	18 Buy rating(s)	19 Buy rating(s)	16 Buy rating(s)	16 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$276.64	$275.95	$253.81	$223.62
Forecasted Upside	4.61% Upside	6.86% Upside	0.91% Upside	1.30% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ABBV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AbbVie Stock vs. The Competition

Type	AbbVie	Healthcare Companies	Broader Market
Consensus Rating Score	2.88	2.31	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	4.61% Upside	764.10% Upside	19.20% Upside
News Sentiment Rating	Positive News See Recent ABBV News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/16/2026	Cantor Fitzgerald 5 of 5 stars	Carter Gould 4 of 5 stars	Reiterated Rating	Overweight
9/10/2026	HSBC 3 of 5 stars	Rajesh Kumar Not Rated	Boost Target	Buy	$300.00 ➝ $315.00	+25.48%
9/8/2026	Bank of America 4 of 5 stars	Geoff Meacham 4 of 5 stars	Reiterated Rating	Buy
8/20/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Amsellem Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$298.00 ➝ $303.00	+14.07%
8/17/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$295.00 ➝ $300.00	+20.38%
8/13/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alexandria Hammond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$300.00	+20.42%
8/11/2026	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Navann Ty Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$218.00 ➝ $247.00	-1.15%
8/5/2026	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy
8/4/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C) ➝ Buy (B-)
8/4/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vamil Divan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$261.00 ➝ $288.00	+17.73%
Get the Latest News and Ratings for ABBV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.
8/3/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$296.00	+20.69%
8/3/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gary Nachman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$282.00 ➝ $290.00	+15.39%
7/29/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$275.00 ➝ $300.00	+13.86%
7/15/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$230.00 ➝ $260.00	+6.23%
7/13/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Yee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$230.00 ➝ $260.00	+5.29%
7/13/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan David Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$258.00 ➝ $300.00	+20.97%
7/10/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Trung Huynh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$260.00 ➝ $280.00	+12.11%
7/9/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$260.00 ➝ $280.00	+10.68%
6/23/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform
5/15/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$235.00	+10.71%
4/30/2026	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
3/9/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
1/28/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Asad Haider Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$223.00	+0.58%
1/20/2026	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luisa Hector Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$275.00	+28.28%
11/13/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Sector Outperform	$280.00	+18.10%
11/3/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gary Nachman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$256.00	+17.36%
8/7/2025	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$214.00	+8.98%
2/3/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Srikripa Devarakonda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$211.00 ➝ $217.00	+14.50%
11/22/2024	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$206.00	+19.64%
11/4/2024	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Toung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy
10/7/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$195.00 ➝ $225.00	+16.22%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:36 PM ET.

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, September 24, 2026. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

AbbVie
Bull Case

Here are some ways that investors could benefit from investing in AbbVie:

AbbVie recently secured European Commission approval for Rinvoq for children aged two and older with active polyarticular juvenile idiopathic arthritis, expanding the drug's addressable population to 11 approved indications in Europe and reinforcing its long-term growth potential in the immunology sector.
The company demonstrated strong financial performance in the most recent quarter, reporting revenue of $16.99 billion, which exceeded the consensus estimate of $16.80 billion and represented a 10.2% year-over-year increase, while also beating earnings per share estimates with $3.65 compared to the expected $3.61.
AbbVie has established a partnership with Iambic, a company that recently filed for an IPO, to accelerate AI-driven drug discovery in immunology, neuroscience, and oncology, providing the firm with access to advanced computational capabilities and future pipeline opportunities.
Investors can benefit from a consistent income stream as AbbVie has increased its dividend for 53 consecutive years, currently offering a yield of 2.61% with a quarterly payment of $1.73 per share, supported by a payout ratio that remains manageable relative to its earnings power.
The stock is trading at $265.03, which is near its 52-week high of $269.39, reflecting strong market confidence and a consensus rating of Moderate Buy with an average price target of $276.64, suggesting further upside potential as institutional investors continue to increase their stakes.

AbbVie
Bear Case

Investors should be bearish about investing in AbbVie for these reasons:

AbbVie is trading at a price-to-earnings ratio of 74.87, which is significantly elevated compared to many peers, raising concerns about valuation sustainability as some analysts argue that revenue pressure and weakening earnings support a sell view despite recent beats.
The company faces challenges in its oncology portfolio, with Imbruvica experiencing decline, and while AbbVie is working to rebuild this segment with newer therapies, the transition period may impact overall revenue growth and market perception of the company's oncology leadership.
Recent insider activity includes significant share sales, such as EVP Nicholas Donoghoe selling 32,710 shares in August 2026, which may signal reduced confidence from company executives or a desire to diversify personal holdings, potentially affecting investor sentiment.
AbbVie's return on equity is negative at 422.07%, indicating that the company is not efficiently generating profits from its shareholders' equity, which could be a concern for value-oriented investors looking for strong capital efficiency metrics.
The stock's beta of 0.29 suggests low volatility relative to the market, but this also means it may underperform in strong bull markets, and the current price of $265.03 leaves limited room for short-term gains before hitting resistance levels near its 52-week high.

ABBV Forecast - Frequently Asked Questions

According to the research reports of 25 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $276.64, with a high forecast of $315.00 and a low forecast of $223.00.

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 5 hold ratings, 18 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABBV shares.

According to analysts, AbbVie's stock has a predicted upside of 4.61% based on their 12-month stock forecasts.

Over the previous 90 days, AbbVie's stock had 3 upgrades by analysts.

AbbVie has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, BNP Paribas Exane, Canaccord Genuity Group, Cantor Fitzgerald, Citigroup, Erste Group Bank, Guggenheim, HSBC, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Royal Bank Of Canada, UBS Group, Weiss Ratings, Wells Fargo & Company, and Wolfe Research in the past 90 days.

Analysts like AbbVie more than other "healthcare" companies. The consensus rating for AbbVie is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ABBV compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With AbbVie Recommendations

MarketBeat monitors more than a dozen sources for AbbVie analyst ratings, with the most recent rating issued on 9/16/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbbVie (ABBV) Stock Forecast & Price Target